48 Result(s)

Article

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

To evaluate the economic burden and treatment patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab, a C5 inhibitor, who were defined as blood transfusion-dependent (TD) v...

Wendy Y. Cheng, Sujata P. Sarda, Nikita Mody-Patel… in Advances in Therapy (2021)

Article

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

Therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) patients are continuously advancing. We described mCRPC treatment patterns in the US from 2013 to 2019.

Neal D. Shore, François Laliberté, Raluca Ionescu-Ittu… in Advances in Therapy (2021)

Article

Correction to: Augmentation in Healthcare Utilization of Patients with Opioid Use Disorder After Methadone Maintenance Treatment: A Retrospective Nationwide Study

A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01712-y

Chieh-Liang Huang, I-Ju Tsai, Wen-Chi Lin, Ing-Kang Ho… in Advances in Therapy (2021)

Article

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibit...

Sanjay Asrani, Jason Bacharach, Edward Holland, Hayley McKee… in Advances in Therapy (2020)

Article

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2

To describe the changes in endothelial cell density (ECD), the coefficient of variation (CV), the percentage of hexagonal cells (%HEX), and central corneal thickness (CCT) following 3 months of therapy with ne...

C. Ellis Wisely, Huan Sheng, Theresa Heah, Terry Kim in Advances in Therapy (2020)

Article

Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”

Hai**g Guan, Yanan Sheng, Wanjie Guo, Sheng Han, Luwen Shi in Advances in Therapy (2020)

Article

YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

Ticagrelor is an oral, reversible, direct-acting P2Y₁₂ receptor inhibitor approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In China, drug intensive monitoring regulations for...

**n Du, Yang Zheng, ** Yang, Shuren Ma, Zaixin Yu, ** Su, Junbo Ge… in Advances in Therapy (2019)